-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Valsartan/Amlodipine Tablets (I) of Shijiazhuang Sihua Pharmaceutical Group Approved
Category:
发布时间：2022-09-26
【概要描述】
Recently, Shijiazhuang Sihua Pharmaceutical Group announced another significant achievement in its research and development efforts: the Class 4 chemical drug valsartan amlodipine tablets (I), developed by the company, has been granted a Drug Registration Certificate by the National Medical Products Administration and is deemed to have passed the evaluation of quality and therapeutic equivalence for generic drugs.
Recently, Shijiazhuang Sihua Pharmaceutical Group announced another significant achievement in its research and development efforts: the Class 4 chemical drug valsartan amlodipine tablets (I), developed by the company, has been granted a Drug Registration Certificate by the National Medical Products Administration and is deemed to have passed the evaluation of quality and therapeutic equivalence for generic drugs.
According to reports, Valsartan/Amlodipine Tablets (I) are primarily indicated for the treatment of essential hypertension and for patients whose blood pressure is not adequately controlled with monotherapy. Hypertension is a common chronic disease, and Valsartan/Amlodipine Tablets (I) is the only single-tablet combination antihypertensive agent included in the National Essential Medicines List; it is also the first compound solid dosage form developed by Shijiazhuang Sihua Pharmaceutical to receive regulatory approval. Single-tablet combination formulations have emerged as a new trend in the management of hypertension due to their ability to reduce the number of pills patients need to take, enhance convenience of use, and improve treatment adherence and efficacy.
In recent years, Shijiazhuang Sihua Pharmaceutical has accumulated substantial R&D achievements, which have provided strong momentum for the company’s competitive development and continuously elevated its industrial chain toward the high end of the value chain. Since the beginning of this year, the company has obtained 30 product approvals, including 20 formulation approvals, placing it at the forefront of the industry in terms of approval volume.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091